ECSP088704A - Derivados de tieno-piridina como inhibidores de mek - Google Patents

Derivados de tieno-piridina como inhibidores de mek

Info

Publication number
ECSP088704A
ECSP088704A EC2008008704A ECSP088704A ECSP088704A EC SP088704 A ECSP088704 A EC SP088704A EC 2008008704 A EC2008008704 A EC 2008008704A EC SP088704 A ECSP088704 A EC SP088704A EC SP088704 A ECSP088704 A EC SP088704A
Authority
EC
Ecuador
Prior art keywords
pyridine derivatives
tieno
mek inhibitors
substituted
mapkk
Prior art date
Application number
EC2008008704A
Other languages
English (en)
Inventor
Daniel Christopher Brookings
Jeremy Martin Davis
Barry John Langham
James A Johnson
Martin Clive Hutchings
Sarah Catherine Archibald
Judi Charlotte Neuss
Original Assignee
Ucb Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ucb Pharma Sa filed Critical Ucb Pharma Sa
Publication of ECSP088704A publication Critical patent/ECSP088704A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

Una serie de derivados de tieno[2,3-b]piridina que están sustituidos en la posición 2 con un resto anilino sustituido, que son inhibidores selectivos de las enzimas MEK (MAPKK)humanas, son por consiguiente beneficiosos en medicina, por ejemplo en el tratamiento de afecciones inflamatorias, autoinmunes, cardiovasculares, proliferativas (con inclusión de las oncológicas) y nociceptivas
EC2008008704A 2006-01-31 2008-08-28 Derivados de tieno-piridina como inhibidores de mek ECSP088704A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0601962.4A GB0601962D0 (en) 2006-01-31 2006-01-31 Therapeutic agents

Publications (1)

Publication Number Publication Date
ECSP088704A true ECSP088704A (es) 2008-09-29

Family

ID=36100789

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2008008704A ECSP088704A (es) 2006-01-31 2008-08-28 Derivados de tieno-piridina como inhibidores de mek

Country Status (26)

Country Link
US (3) US8283359B2 (es)
EP (1) EP1981892B1 (es)
JP (1) JP5249787B2 (es)
KR (1) KR101446919B1 (es)
CN (1) CN101379067B (es)
AU (1) AU2007211377B2 (es)
BR (1) BRPI0708016B1 (es)
CA (1) CA2640594C (es)
CY (1) CY1115404T1 (es)
DK (1) DK1981892T3 (es)
EA (1) EA016128B1 (es)
EC (1) ECSP088704A (es)
ES (1) ES2471970T3 (es)
GB (1) GB0601962D0 (es)
HR (1) HRP20140503T1 (es)
IL (1) IL192603A (es)
MY (1) MY146387A (es)
NO (1) NO341064B1 (es)
NZ (1) NZ569638A (es)
PL (1) PL1981892T3 (es)
PT (1) PT1981892E (es)
RS (1) RS53342B (es)
SI (1) SI1981892T1 (es)
UA (1) UA95939C2 (es)
WO (1) WO2007088345A1 (es)
ZA (1) ZA200807447B (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0601962D0 (en) 2006-01-31 2006-03-15 Ucb Sa Therapeutic agents
GB0616214D0 (en) * 2006-08-15 2006-09-27 Ucb Sa Therapeutic Agents
GB0714384D0 (en) 2007-07-23 2007-09-05 Ucb Pharma Sa theraputic agents
CA2708176A1 (en) * 2007-12-21 2009-07-02 Genentech, Inc. Azaindolizines and methods of use
WO2009093008A1 (en) 2008-01-21 2009-07-30 Ucb Pharma S.A. Thieno-pyridine derivatives as mek inhibitors
GB0811304D0 (en) * 2008-06-19 2008-07-30 Ucb Pharma Sa Therapeutic agents
JP5503930B2 (ja) * 2009-09-18 2014-05-28 住友化学株式会社 ３−アミノ−１−ｔｅｒｔ−ブトキシカルボニルピペリジンの精製方法およびそのクエン酸塩
US9376709B2 (en) 2010-07-26 2016-06-28 Biomatrica, Inc. Compositions for stabilizing DNA and RNA in blood and other biological samples during shipping and storage at ambient temperatures
EP2598661B1 (en) 2010-07-26 2017-09-27 Biomatrica, INC. Compositions for stabilizing dna, rna and proteins in saliva and other biological samples during shipping and storage at ambient temperatures
US9725703B2 (en) 2012-12-20 2017-08-08 Biomatrica, Inc. Formulations and methods for stabilizing PCR reagents
EP2959013A2 (en) 2013-02-25 2015-12-30 Novartis AG Novel androgen receptor mutation
EA201690089A1 (ru) 2013-06-11 2017-04-28 Латвийский Институт Органического Синтеза ТИЕНО[2,3-b]ПИРИДИНЫ КАК МОДУЛЯТОРЫ СОСТОЯНИЯ МНОЖЕСТВЕННОЙ ЛЕКАРСТВЕННОЙ УСТОЙЧИВОСТИ
US20160135446A1 (en) 2013-06-13 2016-05-19 Biomatrica, Inc. Cell stabilization
WO2015191632A1 (en) 2014-06-10 2015-12-17 Biomatrica, Inc. Stabilization of thrombocytes at ambient temperatures
CN105384754B (zh) * 2014-09-02 2018-04-20 上海科州药物研发有限公司 作为蛋白激酶抑制剂的杂环类化合物及其制备方法和用途
US20190008859A1 (en) 2015-08-21 2019-01-10 Acerta Pharma B.V. Therapeutic Combinations of a MEK Inhibitor and a BTK Inhibitor
ES2946184T3 (es) 2015-12-08 2023-07-13 Biomatrica Inc Reducción de la velocidad de eritrosedimentación
JP7212956B2 (ja) 2017-05-19 2023-01-26 エヌフレクション セラピューティクス インコーポレイテッド 皮膚障害の処置用のピロロピリジン－アニリン化合物
ES2913213T3 (es) * 2017-05-19 2022-06-01 Nflection Therapeutics Inc Compuestos heteroaromáticos de anilina condensados para el tratamiento de trastornos dérmicos
CN109836434B (zh) * 2017-11-27 2020-09-25 上海宇耀生物科技有限公司 噻吩并环类化合物及其合成方法和应用
EP3883552B1 (en) 2018-11-20 2025-04-09 NFlection Therapeutics, Inc. Cyanoaryl-aniline compounds for treatment of dermal disorders
CN113473986B (zh) 2018-11-20 2024-10-11 恩福莱克逊治疗有限公司 用于治疗皮肤疾病萘啶酮苯胺化合物
WO2020106305A1 (en) 2018-11-20 2020-05-28 Nflection Therapeutics, Inc. Thienyl-aniline compounds for treatment of dermal disorders
CN113660931B (zh) * 2018-11-20 2024-10-11 恩福莱克逊治疗有限公司 用于治疗皮肤癌的芳基苯胺和杂芳基苯胺化合物
CA3129665A1 (en) 2019-03-21 2020-09-24 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
KR20220098759A (ko) 2019-11-08 2022-07-12 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 키나제 억제제에 대해 내성을 획득한 암의 치료 방법
CN111138449B (zh) * 2020-01-15 2022-11-29 四川大学华西医院 双靶向erk1和erk5抑制剂的制备及其抗肿瘤应用
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
CN117157065A (zh) 2021-01-21 2023-12-01 恩福莱克逊治疗有限公司 吡咯并吡啶-苯胺化合物的晶型
JP2024521788A (ja) 2021-05-27 2024-06-04 ミラティ セラピューティクス， インコーポレイテッド 併用療法
KR20240125577A (ko) 2021-11-23 2024-08-19 엔플렉션 테라퓨틱스, 인코포레이티드 피롤로피리딘-아닐린 화합물의 제형
GB202205203D0 (en) 2022-04-08 2022-05-25 UCB Biopharma SRL Combination with inhibitor
CN118973580A (zh) 2022-04-08 2024-11-15 米拉蒂治疗股份有限公司 包含sos1抑制剂和mek抑制剂的组合疗法
EP4788839A1 (en) 2023-10-03 2026-08-12 Institut National de la Santé et de la Recherche Médicale Methods of prognosis and treatment of patients suffering from melanoma

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE344791T1 (de) 1997-07-01 2006-11-15 Warner Lambert Co 2-(4-brom or 4-iod phenylamino)benzoesäurederivate und ihre anwendung als mek-inhibitoren
US6232320B1 (en) 1998-06-04 2001-05-15 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
BR9916857A (pt) 1999-01-13 2001-12-04 Warner Lambert Co 4 heteroaril diarilaminas
ID30439A (id) 1999-01-13 2001-12-06 Warner Lambert Co Benzoheterosiklus dan penggunaannya sebagai penghambat mek
AU7349801A (en) 2000-07-19 2002-01-30 Warner Lambert Co Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids
WO2003077855A2 (en) 2002-03-13 2003-09-25 Array Biopharma, Inc N3 alkylated benzimidazole derivatives as mek inhibitors
SG2013013339A (en) 2002-03-13 2014-12-30 Array Biopharma Inc N3 alkylated benzimidazole derivatives as mek inhibitors
US7235537B2 (en) 2002-03-13 2007-06-26 Array Biopharma, Inc. N3 alkylated benzimidazole derivatives as MEK inhibitors
US20030225273A1 (en) 2002-03-21 2003-12-04 Michaelides Michael R. Thiopyrimidine and isothiazolopyrimidine kinase inhibitors
GB0214268D0 (en) * 2002-06-20 2002-07-31 Celltech R&D Ltd Chemical compounds
CL2003002287A1 (es) * 2002-11-25 2005-01-14 Wyeth Corp COMPUESTOS DERIVADOS DE TIENO[3,2-b]-PIRIDINA-6-CARBONITRILOS Y TIENEO[2,3-b]-PIRIDINA-5-CARBONITRILOS, COMPOSICION FARMACEUTICA, PROCEDIMIENTO DE PREPARACION Y COMPUESTOS INTERMEDIARIOS, Y SU USO EN EL TRATAMIENTO DEL CANCER, APOPLEJIA, OSTEOPOROSIS
AU2003296414A1 (en) * 2002-12-12 2004-07-09 Pharmacia Corporation Method of using aminocyanopyridine compounds as mitogen activated protein kinase-activated protein kinase-2 inhibitors
AU2004249495A1 (en) 2003-06-20 2004-12-29 Ucb Pharma S.A. Thienopyridone derivatives as kinase inhibitors
CA2528603A1 (en) * 2003-06-20 2004-12-29 Celltech R & D Limited Thienopyridone derivatives as kinase inhibitors
US20050049276A1 (en) 2003-07-23 2005-03-03 Warner-Lambert Company, Llc Imidazopyridines and triazolopyridines
CA2532067C (en) 2003-07-24 2010-12-21 Stephen Douglas Barrett N-methyle-substituted benzamidazoles
US7144907B2 (en) 2003-09-03 2006-12-05 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
EP1670804A2 (en) * 2003-09-10 2006-06-21 GPC Biotech AG Heterobicyclic compounds as pharmaceutically active agents
KR101190912B1 (ko) 2003-11-19 2012-10-12 어레이 바이오파마 인크. Ｍｅｋ의 헤테로시클릭 억제제 및 그의 사용 방법
US7217723B2 (en) 2004-02-02 2007-05-15 Eisai Co., Ltd. Heterocyclic compound having oxime group
AU2006284751A1 (en) 2005-09-01 2007-03-08 Array Biopharma Inc. Raf inhibitor compounds and methods of use thereof
NZ567140A (en) 2005-10-07 2011-09-30 Exelixis Inc Azetidines as MEK inhibitors for the treatment of proliferative diseases
GB0601962D0 (en) 2006-01-31 2006-03-15 Ucb Sa Therapeutic agents
TW200808769A (en) 2006-04-18 2008-02-16 Astrazeneca Ab Therapeutic compounds
GB0616214D0 (en) 2006-08-15 2006-09-27 Ucb Sa Therapeutic Agents
CA2658725A1 (en) 2006-08-16 2008-02-21 Exelixis, Inc. Using pi3k and mek modulators in treatments of cancer
WO2008076415A1 (en) 2006-12-14 2008-06-26 Exelixis, Inc. Methods of using mek inhibitors
GB0714384D0 (en) 2007-07-23 2007-09-05 Ucb Pharma Sa theraputic agents
WO2009093008A1 (en) 2008-01-21 2009-07-30 Ucb Pharma S.A. Thieno-pyridine derivatives as mek inhibitors
GB0811304D0 (en) 2008-06-19 2008-07-30 Ucb Pharma Sa Therapeutic agents

Also Published As

Publication number Publication date
EP1981892A1 (en) 2008-10-22
JP2009525317A (ja) 2009-07-09
AU2007211377A1 (en) 2007-08-09
CN101379067A (zh) 2009-03-04
ES2471970T3 (es) 2014-06-27
US20090149437A1 (en) 2009-06-11
EA200801684A1 (ru) 2009-04-28
KR20080095870A (ko) 2008-10-29
HK1125924A1 (en) 2009-08-21
BRPI0708016B1 (pt) 2021-07-06
RS53342B (sr) 2014-10-31
IL192603A0 (en) 2009-02-11
JP5249787B2 (ja) 2013-07-31
HRP20140503T1 (hr) 2014-07-04
BRPI0708016A2 (pt) 2011-05-17
CA2640594A1 (en) 2007-08-09
PL1981892T3 (pl) 2014-08-29
CA2640594C (en) 2014-12-23
IL192603A (en) 2013-12-31
NZ569638A (en) 2010-08-27
US20120329774A1 (en) 2012-12-27
US8394822B2 (en) 2013-03-12
AU2007211377B2 (en) 2012-03-01
MY146387A (en) 2012-08-15
SI1981892T1 (sl) 2014-07-31
KR101446919B1 (ko) 2014-10-07
CY1115404T1 (el) 2017-01-04
NO20083739L (no) 2008-08-29
PT1981892E (pt) 2014-06-23
ZA200807447B (en) 2009-11-25
US8283359B2 (en) 2012-10-09
NO341064B1 (no) 2017-08-14
WO2007088345A1 (en) 2007-08-09
GB0601962D0 (en) 2006-03-15
UA95939C2 (en) 2011-09-26
US20130150573A1 (en) 2013-06-13
CN101379067B (zh) 2011-03-23
EA016128B1 (ru) 2012-02-28
DK1981892T3 (da) 2014-06-23
EP1981892B1 (en) 2014-03-12
US8604051B2 (en) 2013-12-10

Similar Documents

Publication Publication Date Title
MY146387A (en) Thieno-pyridine derivatives as mek inhibitors
CO6270229A2 (es) Derivados de tiazol fusionados como inhibidores de quinasa
NO20060279L (no) Thienopyridonderivater som kinaseinhibitorer
DK2519527T3 (da) Thieno[2,3-b]pyridindion-aktivatorer af ampk og terapeutiske anvendelser deraf
AR086995A1 (es) Metodos y composiciones para producir plantas con esterilidad masculina
WO2008020206A3 (en) Fused thiophene derivatives as mek inhibitors
DK2048978T3 (da) Rygeartikel med restriktor og kammer ud i et
MX344588B (es) Produccion de acidos grasos y derivados de los mismos.
CR20110261A (es) COMPUESTOS PIRAZOLO[1,5-a]PIRIMIDINA SUSTITUIDA COMO IHNIBIDORES DE TRK CINASA
CL2008003280A1 (es) Compuestos derivados de 1h-pirazolo[3,4-b]piridina)-4-aril sustituidas; la composicion farmaceutica que los contiene; y sus procesos de preparacion.
AP2939A (en) Thieno [2,3-B] pyridine derivatives as viral replication inhibitors
CY1120304T1 (el) Ενωσεις microrna και μεθοδοι για τη διαμορφωση της mir-21 δραστικοτητας
MX2009009371A (es) Produccion mejorada de derivados de acidos grasos.
AR081515A1 (es) Agente de sustentacion de un material vitroceramico
DK2021577T3 (da) Konfigurerbart borehulszoneisolationssystem og tilhørende fremgangsmåder
SG196782A1 (en) Compositions and methods for the increased production of isoprene and other products with 6 - phosphogluconolactonase (pgl)
MX2009004883A (es) Piridil sulfoximinas multi-substituidas y su uso como insecticidas.
SI2046797T1 (sl) Derivati furo B pirol ona in njihova uporaba kot inhibitorji cisteinil proteinaze
HRP20150474T1 (xx) PIRIDINOM I KINOLINOM SUPSTITUIRANI PIROLO[1,2-b]PIRAZOL MONOHIDRAT KAO INHIBITOR TGF-BETA
EP1984061A4 (en) COAXIAL PTA BALLOON
BR112014001075A2 (pt) sonda, seu uso, método in vitro para associar uma sonda com um alvo e kit
CU24052B1 (es) Derivados de anilina-pirimidina sustituidos con sulfoximina como inhibidores de quinasas dependientes de ciclina (cdk), y método de producción de los mismos
BRPI0722074A2 (pt) Problemas de perda de circulação em uma zona de um furo de poço, e dispositivo
BRPI0816676A8 (pt) estrutura de furo de corrida para fornalha de fusão e método de reparo do mesmo.
MX2014006088A (es) Biomarcadores para canceres que responden a moduladores de la actividad de hec1.